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Claude Sporte`s,1 Seth M Steinberg,2 David J Liewehr,2 Juan Gea-Banacloche,1
David N. Danforth,3 Daniele N. Avila,1 Kelly E. Bryant,1 Michael C. Krumlauf,1
Daniel H. Fowler,1 Steven Pavletic,1 Nancy M. Hardy,1 Michael R. Bishop,1 Ronald E. Gress1Inflammatory breast cancer (IBC) is a rare clinicopathologic entity with a poor prognosis, lagging far behind
any other form of nonmetastatic breast cancer. Since the advent of systemic chemotherapy over 35 years ago,
only minimal progress has been made in long-term outcome. Although multiple randomized trials of high-
dose chemotherapy and autologous progenitor cell transplantation (ASCT) for the treatment of breast
cancer have yielded disappointing results, these data are not necessarily relevant to IBC, a distinct clinical
and pathologic entity. Therefore, the optimal multimodality therapy for IBC is not well established, and
remains unsatisfactory. We treated 21 women with nonmetastatic IBC with a multimodality strategy includ-
ing high-dose melphalan (Mel)/etoposide and ASCT. The treatment was overall tolerated with acceptable
morbidity, and no post-ASCT 100-day mortality.With a median potential follow-up of approximately 8 years,
the estimated progression-free survival (PFS), event-free survival (EFS), and overall survival (OS) at 6 years
from on-study date are: 67%, 55%, and 69%, respectively. These results from a small phase II study are among
the most promising of mature outcome data for IBC. They strongly suggest, along with results of several
already published phase II trials, that ASCT could play a significant role in the first line treatment of IBC.
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Multimodality therapyINTRODUCTION
Inflammatory breast cancer (IBC) is a rare clinico-
pathologic entity [1] (1%–2% of all breast carcinoma)
with a very poor prognosis. Historically, IBC response
to conventional treatment consisting of surgery or1Experimental Transplantation & Immunology Branch,
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6/j.bbmt.2009.04.018radiation therapy alone was short lived, with a time to
progression of 12 to 15 months with long-term overall
survival (OS) rarely reaching 15%. The mortality rate
in IBC after a local recurrence is close to 100% and
most patients with local recurrence die with metastatic
disease. The advent of successful combination chemo-
therapy regimens, along with local irradiation of the
breast and regional lymphatics has increased the
5-year disease-free survival (DFS) rate to 30% to
35% [2-4], but the long-term survival is still signifi-
cantly inferior to what is being achieved in other
high-risk, nonmetastatic breast cancers (BC) [5]. The
most recent SEER data estimates the median survival
of women with stage IIIB IBC at 2.9 years versus
6.4 years with other locally advanced BC [6]. The opti-
mal multimodality therapy remains unestablished and
current therapy unsatisfactory [7]. Outside of selected
tertiary care centers, the prognosis is even poorer,
mostly because of the aggressive nature of IBC and of
later diagnosis [8].
High-dose chemotherapy followed by autologous
progenitor blood cell transplantation (ASCT) has963
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and is a particularly attractive modality for IBC be-
cause of the diffuse and aggressive nature of the disease
and its propensity to early micrometastasis. From 14
published randomized trials evaluating ASCT efficacy
in high-risk nonmetastatic BC [9-23], has emerged
a de facto general consensus that ASCT does not pro-
vide a substantial therapeutic advantage for high-risk
nonmetastatic BC, although 2 separate meta-analyses
of these trials support a modest (13%-15%) improve-
ment in event-free survival (EFS) (but not OS) with
ASCT [24,25]. No such assertion of consensus, how-
ever, can be made for IBC from these studies because
they either specifically excluded subjects with IBC or
lacked power for meaningful subset analysis (a total
of 30 of 6063 enrolled patients may have had IBC).
The only outcome data on large numbers of IBC
patients treated with ASCT originate from the trans-
plant registries of the Center for International Blood
and Marrow Transplant Research (CIBMTR) and the
European Blood and Marrow Transplant (EBMT)
Solid Tumors Working Party. They are suggestive of
a beneficial effect of ASCT, but have not been formally
reported. In its 2000 summary report, the CIBMTR
reported a 57% 3-year OS for nonmetastatic IBC,
data based on 811 women who underwent ASCT
between 1991and 1997 (no EFS is available). The
EBMT Solid Tumors Working Party briefly reported
a median PFS of 57 months on 537 transplanted IBC
patients [26]. These data should be interpreted with
caution, as they arise from unavoidably heterogeneous
populations, both in disease status and specific treat-
ment modality.
Several phase II studies of ASCT in nonmetastatic
IBC have been conducted, almost invariably, suggest-
ing a substantial benefit over conventional therapy, but
most also report on short follow-up of 2 to 3 years.
Here, we report mature data of the National Cancer
Institute (NCI)’s experience with ASCT in the treat-
ment of IBC and review the available literature.METHODS
Patient Population
Between September 1996 and September 2008, 21
patients with nonmetastatic IBC were enrolled onto
the NCI study 96-C-0104 to evaluate the role of pac-
litaxel and cyclophosphamide (TC) followed by high-
dose melphalan/etoposide (ME) and ASCT in the
treatment of IBC. All patients were required to have
a diagnosis of carcinoma of the breast, histologically
confirmed by the Laboratory of Pathology of the
NCI. The diagnosis of IBC was based on the classical
clinical syndrome including erythema and edema with
peau d’orange appearance. The presence of dermal
lymphatic involvement with tumor cells was not arequirement for diagnosis; however, patients without
the typical clinical signs, but with evidence of dermal
lymphatic invasion on skin biopsy were also included
(2 of the 21 patients).
To be eligible, all patients treated for their disease
before enrollment on study (chemotherapy and/or defin-
itive surgery)wererequired tohavenot failed this therapy
and to have no delay between the prior therapy and ther-
apy on study. Other eligibility requirements included:
Karnofsky Performance Status .70%, creatinine clear-
ance .60 mL/min, aspartate aminotransferase (AST)
and alanine aminotransferase (ALT)\3 times or biliru-
bin \1.5 times the upper limit of normal, absolute
neutrophil count (ANC) .1000/mm3, platelet count
.90,000/mm3, cardiac ejection fraction .45% at rest,
and carbon monoxide diffusing capacity (DLCO)
.50% of the predicted value. This study was conducted
with the approval of the NCI institutional review board.
All patients gave written informed consent.Treatments
Induction chemotherapy; paclitaxel/
cyclophosphamide (TC)
The followingTCregimenwas given every 4weeks
for 3 to 7 cycles, to achievemaximum clinical response:
paclitaxel: 53.3 mg/m2/day continuous intravenous
(i.v.) infusion for 3 consecutive days (total dose over
72 hours: 160 mg/m2) through a permanent central
venous access device, cyclophosphamide: 900 mg/m2/
day i.v. over 1 hour, daily for 3 days (total dose 2700
mg/m2) andmesna: daily dose of 30%of the cyclophos-
phamide daily dose. Premedication for paclitaxel,
(dexamethasone, cimetidine, and diphenhydramine),
standard antiemetics (5-HT3 antagonists) and hydra-
tion precyclophosphamidewere administered to all pa-
tients. granulocyte-colony stimulating factor (G-CSF):
5 m/kg/day subcutaneously (s.c.) was started on day 5 of
each cycle and continued until ANC.1000 cells/mm3;
during cycle 2 (peripheral blood stem cell [PBSC]
mobilization), the dose was increased to 5 m/kg
twice daily until the last day of apheresis.
Doxorubicin/cyclophosphamide (AC)
Additionally, all patients received an anthracy-
cline-based regimen, either prior to enrollment on
study or as part of the pretransplant induction chemo-
therapy on study. Patients who had not received prior
anthracycline received, following TC chemotherapy,
4 cycles of doxorubicin: 60 mg/m2 i.v. rapid infusion,
and cyclophosphamide: 600 mg/m2 intravenously on
day 1 (AC) every 3 weeks.
Apheresis for PBSC
PBSC were collected and cryo-preserved after the
second TC cycle. When the white blood cell count
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CD341 count was obtained daily. Once the CD341
count was .20/mL, daily 15 to 25-liter apheresis
began. Apheresis could also be started for WBC
.5000/mm3. The target CD341 cell dose was 4.0 
106 cells/kg of body weight with a required minimum
total of 2.0  106 CD341 cells/kg to proceed with
high-dose chemotherapy and ASCT.
Thus, prior to ASCT, all patients had received an
anthracycline-based regimen and a minimum of 3
cycles of TC. Patients receivingTC in the neoadjuvant
setting may have received additional cycles (maximum,
7 cycles) until maximum response.
Preparative regimen; melphalan/etoposide (ME)
Before proceeding with the preparative regimen,
a minimum of 21 days since the last cycle of chemo-
therapy, complete hematologic recovery defined as
an ANC of .500/mm3 and absence of nonhemato-
logic toxicity greater than grade 1 (including a cardiac
ejection fraction .45%) were required. ME was given
on days 26, 25, and 24: melphalan 53.3 mg/m2 i.v.
over 30 minutes daily for 3 days (160 mg/m2 total
dose) and etoposide 600 mg/m2 i.v. over 8 hours daily
for 3 days (1800mg/m2 total dose) starting 1 hour after
melphalan infusion completion. PBSCwere infused on
day 0. G-CSF 5 m/kg/day started on day 0 after the
PBSC infusion and continued until the ANC was
$1000/mm3. Herpes simplex virus (HSV) seropositive
patients received acyclovir prophylaxis until discharge
from the hospital then, following hematopoietic recov-
ery, all patients received pneumocystis jerovecii pro-
phylaxis for 6 months.
Locoregional and Additional Therapy
Locoregional therapy was assessed individually.
Surgery (modified radical mastectomy) was performed
either prior to entry on study or following TC. All
patients received radiation therapy starting 6 weeks af-
ter ASCT. Patients usually received 5000 cGy with an
additional 1000 cGy chest wall boost. Patients with
hormone receptor (HR)-expressing tumors received
tamoxifen 20 mg or anastrazole 1 mg daily for 5 years
posttransplant starting after completion of radiation
therapy. Patients with Her-2 overexpressing tumors
did not receive specific antibody therapy.
Disease Evaluation
At entry on study, metastatic disease was excluded
in all patients with a computed tomography (CT)
scan of chest, abdomen, and pelvis, a bone scan,
and a head CT scan or magnetic resonance imaging
(MRI). Tumor markers were not routinely obtained.
All patients were restaged clinically and radiologically
after the first 3 and every 2 subsequent TC cycles.
Prior to ASCT, the restaging also included a repeatbrain CT scan or MRI. Patients underwent a clinical
reevaluation 6 weeks following ASCT, then every 3
months for 2 years, every 6 months for 1 year, and
yearly thereafter. Imaging reevaluations were per-
formed at 6 weeks, then 6, 12, 18, and 24 months
post-ASCT routinely, then only as clinically indicated.
Disease responsewas evaluated as follows: complete re-
sponse (CR): disappearance of all clinical and radio-
logic disease and no new lesion; partial response (PR):
.50% disease reduction in existingmeasurable disease
and nonew lesion; stable disease (SD):\25%change in
existing measurable disease; progressive disease:
.25% increase in existing measurable disease or ap-
pearance of new lesions.
Patients with PD at any reevaluation or patients
with less than PR at the reevaluation immediately be-
fore ASCT were considered treatment failures and
taken off the study. All toxicities for TC and ME
were recorded using the NCI Common Terminology
Criteria 2.0 version.
Statistical Methods
The durations of progression-free survival (PFS),
EFS, and OS were calculated from the date the patient
went on-study, as well as the date of ASCT, until the
date of disease progression (PFS), the date of an event
defined as either the date of disease progression or
death of any cause (EFS), the date of death from any
cause (OS), or last follow-up as appropriate. The prob-
abilities of these outcomes as a function of time were
determined by the Kaplan-Meier method. The statisti-
cal significance of the difference between 2 Kaplan-
Meier curves was determined by a 2-tailed log-rank
test; all p-values are reported without adjustment for
multiple comparisons. The median potential follow-
up was calculated as the median of the intervals from
on-study date as well as transplant date until the date
of analysis and provides a reasonable measure of the
maturity of the trial.RESULTS
From September 1996 to September 2008, 21 pa-
tients with nonmetastatic IBC were enrolled in the
study. Patients characteristics and outcome are sum-
marized in Tables 1 and 2. The mean age at entry on
study was 50.3 years (range: 35-67 years) and 11 pa-
tients (50%) were postmenopausal. Fifty-two percent
and 60% of the tumors were HR positive and Her-2
overexpressed, respectively. Ten patients (48%) had
received some form of treatment prior to entry on
study (neo-adjuvant chemotherapy and/or definitive
surgery). Twelve of 21 patients had disease evaluable
for the TC induction chemotherapy: there were 11
(92%) responses (7 CR: 58% and 4 PR: 33%) and 1
SD (9%). There was 1 pathologic CR (9%). The
Table 1. Patients Characteristics
Pts Age at Entry ER / PR /Her-2 Post Menop. Clinical IBC Dermal TLI Initial Tumor Size (cm)
1 41 2 / 2 / + 2 + ? 13
2 35 + / +/ + 2 + + 10
3 59 2 / 2 / + 2 + + 2.5
4 60 + / + / 2 + + + 12
5 62 + / 2 / ? + + ? 5
6 41 2/ 2 / + 2 + 2 no mass
7 39 + / + / + 2 + + no mass
8 46 2 / 2 / ? 2 + + 12
9 57 2 / 2 / + + + + no mass
10 68 + / 2 / 2 + + + 3.2
11 54 2 / 2 / + + + + 7
12 43 + / + / 2 2 2 + 4
13 44 + / + / 2 + 2 + 4
14 56 2 / 2 / + + + + 5.5
15 36 2 / 2 / + 2 + 2 7
16 45 + / 2 / + + + + 5
17 51 + / 2 / + + + + no mass
18* 60 2 / 2 / 2 + + ? no mass
19 35 + / + / 2 2 + + no mass
20 60 2 / 2 / 2 2 + 2 no mass
21 66 + / 2 / + + + + 3
ER/PR indicates estrogen/progesterone receptor; TLI, tumor lymphatic invasion; IBC, inflammatory breast cancer.
*Patient presented at diagnosis with bilateral IBC.
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subsequent AC regimen. Therefore, all evaluable pa-
tients achieved the minimum required response and
20 of 21 patients proceeded to the high-dose chemo-
therapy. The only patient not undergoing ASCT
died of sepsis after delaying seeking treatment during
neutropenia following a TC cycle.
The toxicity of the treatment strategy (TC fol-
lowed or preceded by AC, followed by high-doseTable 2. Patients Outcome
Pts
Prior
Therapy+
No. of TC
Cycles
Clinical
Response to
TC
Pathologic
Response to
TC
Resi
Tumor
MRM
1 + 3 NE NE residual
2 + 4 NE NE residual
3 + 3 NE NE 2.4
4 2 4 SD PR 5
5 2 7 CR PR residual
6 2 5 CR PR residual
7 2 5 PR PR 7
8 2 5 PR PR residual
9 + 4 NE NE 3.5
10 + 3 NE NE 6
11 2 5 PR PR residual
12 + 5 NE NE 4
13 + 5 NE NE 4
14 2 5 CR CR -
15 2 5 CR PR residual
16 2 5 CR PR 3 cm
17 2 4 PR NE na
18* + 3 CR PR residual
19 + 3 NE NE residual
20 + 3 NE NE 6
21 2 3 CR PR 2.1
TC indicates paclitaxel/cyclophosphamide; MRM, modified radical mastectomy
event-free survival; OS, overall survival; ASCT, autologous progenitor cell tran
*Prior therapy usually consisted of receiving AC and /or definitive surgery priME and ASCT) is within generally acceptable limits,
and was previously reported in a larger cohort of
patients [27]. The hematologic toxicity of the TC reg-
imen was noteworthy, but manageable, with brief
hospitalization for empiric antibiotic therapy of febrile
neutropenia occurring in 55% of the cycles. All 21 pa-
tients had adequate PBSC collections. Mortality
within 100 days of ASCT was zero. Three of the
8 deaths were not related to disease progression:dual
Size at
(cm)
Lymph Nodes
at MRM
(Positive/
Total)
EFS from on
Study
(Months)
EFS from
ASCT
(Months)
OS from on
Study
(Months)
foci 0 / 15 142 + 140 + 142 +
foci 7 / 28 97 + 94 + 97 +
12 /12 136 + 133 + 136 +
24 /24 84 76 85
foci 11 / 11 59 48 59
foci 7 / 14 113 + 106 + 113 +
6 /14 106 + 96 + 106 +
foci 3 / 15 15 8.8 95 +
16 / 16 24 21 75
27 / 28 11 6.9 11
foci 2 / 14 98 + 90 + 98 +
20 / 20 82 + 76 + 82 +
15 / 16 79 + 72 + 79 +
0 / 6 68 + 59 + 68 +
foci 0 / 11 21 12 22
3 / 11 55 + 46 + 55 +
na 3.4 na 3.4
foci 0 / 0 14 9.0 33
foci 7 / 17 12 9.3 18
6 / 12 23 20 25 +
8/12 9 + 1.4 + 8.6 +
; NE, not evaluable; CR, complete remission; PR, partial remission; EFS,
splantation.
or to entry on study.
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a 67-year-old woman died 6 months post-ASCT
from progressive multifocal leukoencephalopathy in
the absence of BC recurrence (confirmed at autopsy);
and a 66-year-old patient died of pneumonia, dis-
ease-free, 47 months post-ASCT. Seven patients had
a disease recurrence; 3 patients relapsed at 9 months,
and 1 each at 12, 20, 21, and 78 months following
ASCT. It is noteworthy that not achieving a pathologic
CR following TC chemotherapy was not predictive of
a shorter EFS; 5 of the 10 patients (50%) achieving
a pathologic PR are still clinically free of disease
(EFS: 1 patient at 81 months and 4 patients from
581 to 1231months), whereas the patient with a path-
ologic CR prior to ASCT has a 661 month EFS.Figure 1. Survival curves (Kaplan-Meyer) for PFS, EFS, andOS from on-study d
rank test are indicated).Themedian follow-up was 8.4 years from on-study
date (n 5 21) and 8.3 years from transplant date (n 5
20). The probabilities of PFS, EFS, and OS were
67%, 60%, and 75%, respectively, at 3 years and
67%, 55%, and 69%, respectively, at 6 years from the
on-study date (Figure 1a). The survival estimates are
detailed in the Supplemental Table on-line. No statis-
tically significant difference in any of these 3 outcome
measures was seen between HR-positive and HR-neg-
ative patients. Statistically significant differences were
seen in PFS and EFS (but not in OS) from on-study
date between theHer-2overexpression andnonoverex-
pression groups with the following 6-year probabilities
and corresponding 2-tailed log-rank test results for the
comparisons: PFS: 80% versus 50%, P 5 .034; EFS:ate.(a) All patients; (b) patients stratified by Her-2 status (P-values of Log
968 Biol Blood Marrow Transplant 15:963-970, 2009C. Sporte`s et al.73% versus 43%, P 5 .050; OS: 83% versus 54%,
P 5 .15 (Figure 1b, Supplemental Table on-line).DISCUSSION
Since the addition of systemic chemotherapy to
locoregional treatment, now over 30 years ago, and de-
spite some progress in response rate, no substantial
progress has been made in the long-term outcome of
IBC, either by the addition of taxanes or by varying
the drug combinations [4,28]. Newer therapies are
providing invaluable insight in to the disease [29],
but have yet to demonstrate a decidedly superior ther-
apeutic potential in a disease that lags so far behind
other non metastatic BC in long-term survival.
Although high-dose chemotherapy followed by
ASCT has not been found to be beneficial in the treat-
ment of high-risk nonmetastatic BC and has been
largely abandoned for this indication, no data from
randomized clinical trials exist to reach the same con-
clusion for IBC. Data from 2 transplant registries sug-
gest some efficacy of ASCT in treating IBC, although
neither registry has formally reported their results.
Several published phase II studies have found out-
come benefit fromASCT in IBCpatients [30-36]. Pub-
lished studies are summarized inTable 3 alongwithour
data. Viens et al. [30] reported on 17 consecutive IBC
patients with a median follow-up of 36 months (range:
17-52) with a disease-free survival (DFS) of 58.8%
from diagnosis, then subsequently reported a collabo-
rative study in 100womenwith nonmetastatic IBC (Pe-
gase 2 trial [34]) with 3-year estimated relapse-free
survival (RFS) and OS of 44% and 70%, respectively.
Cagnoni et al. [37] reported a cohort of 30 IBC patients
with a median follow-up of 2 years, subsequently ex-
panded to 56 patients with longer follow-up [38] with
DFS of 65% and OS of 70% at 7 years. Ayash et al.
[39] reported on 46 women with IBC with a 30-month
DFS of 64%. The 30-month DFS was estimated at
100% for patients in pathologic CR, 70% with micro-
scopic or 38% with gross disease after ASCT. AdkinsTable 3. Summary of Published Studies of High-Dose Chemothera
Authors N Preparative regimen
Viens 17 Mi, Cy, M 66% at
Cagnoni updated series 30 51 CPDD, Cy, BCNU 70% at
year
Ayash 46 CTCb 64% at
Adkins 47 Various regimens 58% at
Schwartzberg 56 CTCb 53% at
Viens 100 Sequential high-dose 44% at
Arun 24 Cy, Cb 71% at
Dazzi 21 MI, Thiotepa, Cy 54% at
NCI 21 M, Etoposide 67% at
year
Mi indicares Mitoxantrone; Cy, cyclophosphamide; Mel, melphalan; CPDD, ci
Cancer Institute; DFS, disease-free survival; OS, overall survival.et al. [31] reported on 47 consecutive IBC patients: at
a mean follow-up of 30 months, the 30-month esti-
mated DFS and OS were 57% and 59%, respectively.
In the study by Schwartzberg et al. [33], 56 IBCpatients
were treated: with a median follow-up of 47 months,
the 3-year estimated EFS and OS were 53% and
72%. Dazzi et al. [40] investigated the usefulness of
a neo-adjuvant high-dose anthracycline containing
chemotherapy in 21 patients. Although response rate
and outcome were encouraging, there was significant
toxicity, cardiac in particular. It noteworthy that, be-
cause the recurrence-free interval in IBC is historically
considerably shorter than non-IBC, the shortermedian
follow-up in these studies still suggests an encouraging
outcome.
We report here on 21 patients with nonmetastatic
IBC following a treatment regimen successfully pi-
loted in our institution, which includes dose-intensive
paclitaxel/cyclophosphamide induction [41] then
ASCT following high-dose melphalan/etoposide
[27]. As previously reported, the HR status does not
appear to be of added prognostic value in our series,
whereas, unlike what is reported for standard-dose
chemotherapy trials, achieving a pathologic CR with
standard chemotherapy does not appear to be of prog-
nostic significance in our series, which further argues
in favor of an added therapeutic benefit from the
high-dose chemotherapy following the determination
of disease status pathologically. To our knowledge of
the published mature literature on IBC outcome, en-
compassing mostly standard-dose chemotherapy,
these data represent the most favorable outcome in
the first line treatment of this disease and significantly
contributes to the body of evidence in support of
ASCT for IBC, not only by its outcome data but also
by its maturity.
In conclusion, a significant body of phase II data
has now accumulated and matured, indicating that
ASCT may offer a significant benefit in the first-line
treatment of nonmetastatic IBC, and in the unfortu-
nate absence of data from randomized trials to confirm
or invalidate it, it collectively represents the bestpy and Stem Cell Transplantation in IBC
DFS OS Reference
3 years 86% at 3 years [30]
2 years 65% at 7
s
87% at 2 years 70% at 7
years
[37] [38]
30 months 89% at 30 months [39]
4 years 59% at 4 years [31]
3 years 72% at 3 years [33]
3 years 70% at 3 years [34]
2 years 73% at 2 years [32]
4 years 63% ay 4 years [40]
3 years 67% at 6
s
75% at 3 years 75% at 6
years
splatin; CTCb; cyclophosphamide, thiotepa, carboplatin; NCI, National
Biol Blood Marrow Transplant 15:963-970, 2009 969High-Dose Chemotherapy in the Treatment of Inflammatory Breast Canceroutcome data for this disease. Our data, therefore, con-
firm as well as extend available findings; both aspects
are of substantial value in the field of ASCT and IBC
therapy as it now stands. As none of the newer thera-
peutic approaches presently under investigation has
outcome data yet approaching ASCT results (either
in treatment efficacy or data maturity), we believe
that substantial collaborative efforts should be devoted
to validate these results in a well designed and ade-
quately powered phase III randomized trial.ACKNOWLEDGMENTS
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